Canagliflozin Cardiovascular Assessment Study
(World News USA)

Contribution To Literature: The CANVAS trial showed that canagliflozin was superior to placebo at preventing cardiovascular events. Description: The goal of the trial was to evaluate the sodium-glucose cotransporter 2 inhibitor canagliflozin compared with placebo among patients with type 2 diabetes. Study Design Randomized Parallel Placebo Blinded Patients with type 2 diabetes were randomized to canagliflozin (n = 5,795) versus placebo (n = 4,347). Patients in the canagliflozin arm received 300 mg daily or 100 mg daily. Inclusion criteria: Patients with type 2 diabetes and high cardiovascular risk >=30 years of age and history of symptomatic atherosclerotic cardiovascular disease, or >=50...